Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics develops cancer medicines, with its most advanced candidate in Phase 2/3 trials for melanoma. It last closed at $4.74 on Nov 20, down 0.42% on the day. The next earnings report for EIKN is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, EIKN reported EPS of -$1.59. Over its last 4 reports the stock moved an average of 8.4% the session after earnings. Over the last 12 months EIKN insiders bought $52.2M of stock on the open market and sold $0, according to SEC Form 4 filings.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on EIKN
Technical AnalysisPrices may be delayed
The stock is 19% below its 20 day and 48% below its 50 day average. It is 112% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the 52 week low at $4.72, and the nearest resistance the Pivot at $4.89.
| RSI (14) | 32.93 | Weak, oversold below 30 | Neutral |
| MACD | -0.59 | Below its signal line | Bearish |
| Stochastic | 4.9 | Near the bottom of its range | Oversold |
| ADX (14) | 20.5 | Weak trend | |
| Williams %R | -99.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -147.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −19.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.63 | Typical daily range, 13.3% of price |
| RSI (14) | 30.34 | Weak, oversold below 30 | Neutral |
| MACD | -1.51 | Below its signal line | Bearish |
| Stochastic | 6.6 | Near the bottom of its range | Oversold |
| ADX (14) | 13.4 | No clear trend | |
| Williams %R | -99.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -134.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −47.0% | Change over 10 sessions | Bearish |
| ATR (14) | $1.82 | Typical daily range, 38.5% of price |
What happened before
See how EIKN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options FlowPrices may be delayed
90DNo whale options trades in EIKN in the last 90 days.
EIKN Institutional Ownership
Full report →- ▲75 buying vs 17 selling
- ▲Held by funds +9.6 pts
- ▲Funds holding +21
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 98 | 77 | +27.3% |
| In funds' top 10 | 4 | 5 | −20.0% |
| Held by funds | 58.5% | 48.9% | +9.6 pts |
| New / increased | 30 / 45 | 37 / 17 | +38.9% |
| Reduced / sold out | 8 / 9 | 9 / 12 | −19.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
EIKN Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3 | Column Group IV GP, LP10% owner | Buy | 89,200 | $11.56 | $1.0M |
| Feb 6 | Column Group Opportunity III, LP10% owner | Buy | 2,117,760 | $18.00 | $38.1M |
| Feb 4 | Foresite Capital Opportunity Management V, LLC10% owner | Buy | 55,555 | $18.00 | $1000K |
| Feb 4 | Lux Ventures V, L.P.10% owner | Buy | 277,776 | $18.00 | $5.0M |
| Feb 4 | Josh WolfeDirector | Buy | 277,776 | $18.00 | $5.0M |
| Feb 4 | Kenneth C FrazierDirector | Buy | 111,111 | $18.00 | $2.0M |
From SEC Form 4 filings by EIKN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EIKN is in one of them and how their past EIKN trades turned out.
EIKN News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered EIKN in an article yet. Here's the latest on the wider market.
- Eikon Therapeutics Reports Third Quarter 2026 Financial Results
- Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
- Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
About Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company based in Millbrae, California, that is developing medicines for cancer. Its main focus is oncology, and its most advanced candidate, EIK1001, is in Phase 2/3 trials with pembrolizumab for advanced melanoma. The company also has candidates that inhibit PARP1 for ovarian, breast, prostate and pancreatic cancers, plus an early-stage helicase inhibitor. Its medicines are still in clinical development and are not yet sold to patients.
- Headquarters
- Millbrae, CA


